Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation
Furuhjelm C, Warstedt K, Fagerås M, Fälth-Magnusson K, Larsson J, Fredriksson M, Duchén K
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 110 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2011-02-20 · Pediatr Allergy Immunol · vol. 22 · número 5 · págs. 505–514
- Editorial
- Wiley
- Citado
- 166 citas · más que el 99% de estudios similares · 12.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- Acceso abierto (copia en repositorio) · OTHER-OA
- Áreas de investigación
- Fatty Acid Research and Health · Food Allergy and Anaphylaxis Research · Asthma and respiratory diseases
- Palabras clave
- omega-3 fatty acids, pregnancy, lactation, eicosapentaenoic acid, docosahexaenoic acid, plasma phospholipid fatty acids, infantile eczema, food allergy, allergy prevention
- MeSH
- blood, humans, dermatitis, atopic, food hypersensitivity, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, fish oils, immunoglobulin e, treatment outcome, immunity, maternally-acquired, lactation, pregnancy, dietary supplements, adult, infant, infant, newborn, female, maternal nutritional physiological phenomena
7 autores
- Catrin Furuhjelm🇸🇪 · autor de correspondenciaLinköping University
- Kristina Warstedt🇸🇪Linköping University
- Malin Fagerås🇸🇪Linköping University
- Karin Fälth‐Magnusson🇸🇪Linköping University
- J. Larsson🇸🇪Ryhov Hospital Jönköping
- Mats G. Fredriksson🇸🇪Linköping University
- Karel Duchén🇸🇪Linköping University
Resumen
El texto original del estudio, en el idioma en que se publicó.
We have previously reported a protective effect of maternal omega-3 long-chain polyunsaturated fatty acids (ω-3 LCPUFA) supplementation in pregnancy and lactation on IgE-associated eczema and food allergy in the infant during the first year of life. Here we investigate whether the effects of the LCPUFA supplementation on IgE-associated diseases last up to 2 yr of age and assess the relationship between plasma proportions of ω-3 PUFAs and the frequency and severity of infant allergic disease. 145 pregnant women, at risk of having an allergic infant, were randomized to daily supplementation with 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) or placebo starting in the 25th gestational week and continuing through 3.5 months of breastfeeding. Clinical examinations, skin prick tests and analysis of maternal and infant plasma phospholipid fatty acids and infant specific IgE were performed. No difference in the prevalence of allergic symptoms was found between the intervention groups. The cumulative incidence of IgE-associated disease was lower in the ω-3-supplemented group (6/54, 13%) compared with the placebo group (19/62, 30%, p=0.01). Higher maternal and infant proportions of DHA and EPA were associated with lower prevalence of IgE associated disease (p=0.01-0.05) in a dose-dependent manner. Higher maternal and infant proportions of DHA and EPA were found if the infants presented none, when compared with multiple allergic symptoms, (p<0.05) regardless of sensitization. In summary, the ω-3 supplementation offered no obvious preventive effect on the prevalence of clinical symptoms of allergic disease, but the decrease in cumulative incidence of IgE-associated disease seen during the first year still remained until 2 yr of age. Furthermore, high proportions of DHA and EPA in maternal and infant plasma phospholipids were associated with less IgE-associated disease and a reduced severity of the allergic phenotype.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.